So sánh tác động của myo-inositol và metformin đến đặc điểm lâm sàng, hồ sơ nội tiết và chuyển hóa ở phụ nữ vô sinh mắc hội chứng buồng trứng đa nang: Một thử nghiệm ngẫu nhiên có kiểm soát
Tóm tắt
So sánh hiệu quả của myo-inositol và metformin trên các đặc điểm lâm sàng, và hồ sơ nội tiết và chuyển hóa của phụ nữ Việt Nam vô sinh mắc hội chứng buồng trứng đa nang (PCOS).
Từ tháng 6 năm 2018 đến tháng 8 năm 2022, một thử nghiệm ngẫu nhiên được tiến hành tại Trung tâm Nội tiết và Sinh sản Huế về các phụ nữ vô sinh từ 18 đến 40 tuổi mắc hội chứng buồng trứng đa nang. Các đặc điểm lâm sàng, nội tiết và chuyển hóa của những cá nhân này được đánh giá trước và sau 3 tháng điều trị bằng 2g myo-inositol hoặc 1700mg metformin mỗi ngày. Tỷ lệ mang thai tự nhiên, tác dụng phụ và sự dung nạp myo-inositol được ghi nhận.
Từ khóa
#myo-inositol #metformin #hội chứng buồng trứng đa nang #vô sinh #thử nghiệm y khoaTài liệu tham khảo
Lizneva, 2016, Criteria, prevalence, and phenotypes of polycystic ovary syndrome, Fertil Stent, 106, 6, 10.1016/j.fertnstert.2016.05.003
Sortino, 2017, Polycystic ovary syndrome: Insights into the therapeutic approach with inositols, Frontiers Pharmacol, 8, 341, 10.3389/fphar.2017.00341
Zhao, 2023, Insulin resistance in polycystic ovary syndrome across various tissues: An updated review of pathogenesis, evaluation, and treatment, J Ovarian Res, 16, 9, 10.1186/s13048-022-01091-0
Lashen, 2010, Role of metformin in the management of polycystic ovary syndrome. Therapeutic advances in endocrinology metabolism, Ther Adv Endocrinol Metab, 1, 117, 10.1177/2042018810380215
Morley, 2017, On behalf of the royal college of obstetricians and gynaecologists. Metformin therapy for the management of infertility in women with polycystic ovary syndrome, BJOG, 124, e306
Eisenhardt, 2006, Early effects of metformin in women with polycystic ovary syndrome: A prospective randomized, double-blind, placebo-controlled trial, J Clin Endocrinol, 91, 946, 10.1210/jc.2005-1994
Hoeger, 2004, A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: A pilot study, Fertil Steril, 82, 421, 10.1016/j.fertnstert.2004.02.104
Morley, 2017, Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility, Cochrane Database Syst Rev, 11
Pundir, 2018, Inositol treatment of anovulation in women with polycystic ovary syndrome: A meta-analysis of randomised trials, BJOG, 125, 299, 10.1111/1471-0528.14754
Thakur, 2020, Randomised controlled trial: Comparing effects of metformin versus myoinositol versus metformin and myoinositol on ovarian functions and metabolic factors in polycystic ovarian syndrome, Int J Reprod Contracep Obstet Gynecol, 9, 2542, 10.18203/2320-1770.ijrcog20202345
Lee, 2012, Polycystic ovarian syndrome: Role of imaging in diagnosis, Radiographies, 32, 1643, 10.1148/rg.326125503
2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, Fertil Steril, 81, 19, 10.1016/j.fertnstert.2003.10.004
Escobar-Morreale, 2012, Epidemiology, diagnosis and management of hirsutism: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society, Hum Reprod Update, 18, 146, 10.1093/humupd/dmr042
Huang, 2016, Ethnic differences: Is there an Asian phenotype for polycystic ovarian syndrome?, Best Practice Res Clin Obstet Gynaecol, 37, 46, 10.1016/j.bpobgyn.2016.04.001
Mansour, 2022, Ovarian volume, not follicle count, is independently associated with androgens in patients with polycystic ovary syndrome, BMC Endocrine Disorders, 22, 1, 10.1186/s12902-022-01224-y
Grundy, 2005, Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement, Circulation, 112, 2735, 10.1161/CIRCULATIONAHA.105.169404
Einhorn, 2003, American College of Endocrinology position statement on the insulin resistance syndrome, Endocrine Practice, 9, 5, 10.4158/EP.9.S2.5
Zhu, 2018, 2016 Chinese guidelines for the management of dyslipidemia in adults, J Geriatr Cardiol, 15, 1
Cao, 2019, Defining polycystic ovary syndrome phenotype in Vietnamese women, J Obstet Gynaecol Res, 45, 2209, 10.1111/jog.14097
Agrawal, 2019, Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: Randomized controlled trial, Gynecol Endocrinol, 35, 511, 10.1080/09513590.2018.1549656
Prabhakar, 2021, Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles-randomized controlled trial, Gynecol Endocrinol, 37, 332, 10.1080/09513590.2020.1810657
Teede, 2018, Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome, Hum Reprod, 33, 1602, 10.1093/humrep/dey256
Le, 2021, A cross-sectional study on potential ovarian volume and related factors in women with polycystic ovary syndrome from infertile couples, Int J Women's Health, 13, 793, 10.2147/IJWH.S329082
Park, 2007, The metabolic syndrome in young Korean women with polycystic ovary syndrome, Diabetes Res Clin Pract, 77, S243, 10.1016/j.diabres.2007.01.065
Chen, 2006, Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS, Hum Reprod, 21, 2266, 10.1093/humrep/del175
Patel, 2017, Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: A meta-analysis of randomized controlled trials, Curr Med Res Opinion, 33, 1545, 10.1080/03007995.2017.1279597
Genazzani, 2010, Use of metformin in the treatment of polycystic ovary syndrome, Women's Health, 6, 577, 10.2217/WHE.10.43
Oner, 2011, Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome, Eur J Obstet Gynecol Reprod Biol, 159, 127, 10.1016/j.ejogrb.2011.07.005
Genazzani, 2012, Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients, Gynecol Endocrinol, 28, 969, 10.3109/09513590.2012.685205
Zarezadeh, 2022, Inositol supplementation and body mass index: A systematic review and meta-analysis of randomized clinical trials, Obes Sci Pract, 8, 387, 10.1002/osp4.569
Genazzani, 2008, Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome, Gynecol Endocrinol, 24, 139, 10.1080/09513590801893232
Papaleo, 2007, Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction, Gynecol Endocrinol, 23, 700, 10.1080/09513590701672405
Unfer, 2017, Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials, Endocr Connect, 6, 647, 10.1530/EC-17-0243
Hayamizu, 2022, Effects of inositol in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials, J Nutrit Health Food Sci, 10, 1, 10.15226/jnhfs.2022.001189